Cycurion, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Cycurion, Inc. on February 27, 2026, regarding events occurring on February 26, 2026. The Company is an emerging growth company incorporated in Delaware with its principal executive offices in McLean, Virginia. The report addresses the adjournment of a Special Meeting of Stockholders originally scheduled for February 26, 2026.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on corporate governance events rather than financial performance data.
Material Changes and Corporate Actions
- Meeting Adjournment: The Special Meeting was adjourned to Thursday, March 19, 2026, at 12:00 p.m. Eastern Time because the number of votes cast on February 26 was insufficient to constitute a quorum.
- Meeting Purpose: Stockholders are to vote on the issuance of up to 3,314,920 shares of common stock upon the exercise of warrants issued in a private placement closed on December 5, 2025. This issuance is subject to Nasdaq Listing Rule 5635(d) as it may exceed 20% of outstanding shares.
- Record Date: The record date remains January 21, 2026, and applies to the reconvened meeting.
- Proxy Status: Proxies previously submitted will be voted at the reconvened meeting unless revoked. Stockholders who have already voted need not take further action.
Guidance, Outlook, and Risks
The filing does not contain financial guidance, management commentary on future outlook, or specific risk factors beyond the immediate procedural risk of failing to achieve a quorum for the warrant approval. The primary contingency is the successful reconvening of the meeting to secure the necessary votes for the warrant exercise approval.
Key Facts for Investor Verification
- Verify the outcome of the Special Meeting scheduled for March 19, 2026, regarding the approval of the warrant exercise.
- Confirm the total number of shares outstanding to assess the dilution impact of the potential 3,314,920 new shares.
- Review the definitive proxy statement filed on February 2, 2026, for detailed terms of the private placement warrants.
- Monitor subsequent filings for any updates on the quorum status or further adjournments.